Login to Your Account

No Surprises in Pricing, Label for Gilead's Four-Drug Stribild

By Jennifer Boggs
Managing Editor

Wednesday, August 29, 2012

Gilead Sciences Inc. said it expects to have its four-drug, single-tablet regimen Stribild, formerly known as Quad, available to patients by the end of this week, following the drug's approval Monday for treatment-naïve patients with HIV-1 infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription